Associated Papers
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.
Ho DWH et al.
Gut, 2017
27974549 (PubMed )
Supplement: gutjnl-2016-312734supp001.pdf
Select a paper to view details